Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Amiloride sensitizes prostate cancer cells to the reversible tyrosine kinase inhibitor lapatinib by modulating Erbb3 subcellular localization

Cellular and Molecular Life Sciences(2024)10.1007/s00018-024-05540-5Source: DataRank Database

Amiloride sensitizes prostate cancer cells to the reversible tyrosine kinase inhibitor lapatinib by modulating Erbb3 subcellular localization is a research paper published in Cellular and Molecular Life Sciences (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.10)OA: goldTopics (116)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Maria Mudryj,Marc Dall’Era ORCID,P. Ghosh ORCID,Maitreyee K. Jathal ORCID

Live enrichment

PubMed:39725713 PMC:PMC11671466 OpenAlex:https://openalex.org/W4405852648

U.S. Department of Defense

Grant: W81XWH-21-1-0073

Biomedical Laboratory Research and Development, VA Office of Research and Development

Grant: I01BX004423

Comprehensive Cancer Center, University of California, Davis

Grant: P30CA093373

National Institutes of Health

Grant: 3P30CA093373-07S2

Cancer Center Support Grant - P30

National Institutes of Health

Grant: 5R01CA185509-03

(PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc

National Institutes of Health

Grant: 5P30CA093373-06

Cancer Center Support Grant - P30

National Institutes of Health

Grant: 5I01BX004423-03

Target, Function and Mechanism of LLS30 in Castration Resistant Prostate Cancer

FWCI

1.10

Citation Percentile

0.8%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s00018-024-05540-5.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00018-024-05540-5.pdf

publisherhttps://link.springer.com/article/10.1007/s00018-024-05540-5/fulltext.html

journalhttps://doi.org/10.1007/s00018-024-05540-5

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39725713

Fields of Study

Prostate Cancer Treatment and ResearchHER2/EGFR in Cancer ResearchCell Adhesion Molecules Research0301 basic medicine0302 clinical medicine03 medical and health sciencesLapatinibHumansReceptor, ErbB-3MaleProstatic NeoplasmsProtein Kinase InhibitorsCell Line, TumorAmilorideErb-b2 Receptor Tyrosine KinasesCell NucleusAntineoplastic AgentsCell ProliferationReceptors, AndrogenTyrosine Kinase Inhibitors

MeSH Terms

LapatinibTyrosine Kinase InhibitorsAmilorideAntineoplastic AgentsCell NucleusHumansMaleProstatic NeoplasmsReceptors, AndrogenReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3Cell Line, TumorProtein Kinase InhibitorsCell ProliferationReceptor, erbB-3

Keywords

LapatinibProstate cancerCancer researchAndrogen receptorMedicineAmilorideERBB3PharmacologyEpidermal growth factor receptorCancerInternal medicineChemistryTrastuzumabBreast cancerSubcellular localizationHeregulin-1βMaleAgingReceptor, ErbB-3PhysiologyProstate Cancer (rcdc)AndrogenAging (rcdc)ErbB-2ErbB-3Receptors1103 Clinical Sciences (for)Cell Proliferation (mesh)32 Biomedical and Clinical Sciences (for-2020)Male (mesh)Cell Nucleus (mesh)3101 Biochemistry and cell biology (for-2020)Cancer (rcdc)Humans (mesh)TumorProtein Kinase Inhibitors (mesh)Antineoplastic Agents (mesh)5.1 PharmaceuticalsReceptors, Androgen6.1 PharmaceuticalsHeregulin-1 betaErbB-2 (mesh)Original ArticleTumor (mesh)ReceptorProstatic Neoplasms (mesh)Urologic DiseasesBiochemistry & Molecular BiologyClinical SciencesOncology and Carcinogenesis0601 Biochemistry and Cell Biology (for)610Antineoplastic AgentsTyrosine Kinase InhibitorsBiochemistry & Molecular Biology (science-metrix)Erb-b2 Receptor Tyrosine KinasesTyrosine Kinase Inhibitors (mesh)ArticleCell Line5.1 Pharmaceuticals (hrcs-rac)Cell Line, TumorAmiloride (mesh)Medical biochemistry and metabolomics3211 Oncology and carcinogenesis (for-2020)HumansProtein Kinase Inhibitors3202 Clinical Sciences (for-2020)Cell ProliferationCell Nucleus6.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical SciencesAndrogen (mesh)Prostatic NeoplasmsCancer (hrcs-hc)0606 Physiology (for)Urologic Diseases (rcdc)Biochemistry and Cell BiologyErbB-3 (mesh)Lapatinib (mesh)3205 Medical biochemistry and metabolomics (for-2020)

Sustainable Development Goals

SDG 0: Good health and well-being